Biotech Startups

1 investor

ImmunoBiome develops microbiome-based therapeutics targeting intractable immune diseases such as cancer and autoimmune disorders, drawing on immunology, bioinformatics, and microbiome research. The company operates in the biotech and drug development space.

1 investor

ImmunoBlue develops nanoimmunotherapies for cancer treatment by combining nanotechnology and immunotherapy. It operates in the biotech and therapeutics space.

1 investor

Immunocodex develops lipid nanoparticle mRNA-based therapies targeting dendritic cells to induce immune tolerance for the treatment of autoimmune diseases. The company employs a precision approach that aims to re-program immune cells to suppress inflammatory responses while avoiding broad immunosuppression.

1 investor

Yicura is a clinical-stage biotechnology company developing DNA medicines and antibody immunotherapies for cancer, inflammatory, and infectious diseases using proprietary vaccine and antibody platforms.

1 investor

ImmunoScape is a Singapore-based biotechnology company developing high-throughput immune profiling and therapeutic T cell receptor discovery platforms for immunotherapy and cancer treatment. The company was spun off from Singapore's A*STAR research institute and serves the immunotherapy and oncology sectors.

1 investor

ImmunoStep produces monoclonal antibodies for research use, including recombinant antibodies that target specific T-cell receptors for flow cytometry applications in immunology research.

1 investor

Immunovant is a clinical-stage immunology company developing targeted therapies based on anti-FcRn technology for people with autoimmune diseases.

1 investor

ImmunoVec develops programmable DNA-based in vivo medicines that use cell type- and cell state-specific synthetic promoters to control payload expression in targeted cells for treating cancer and autoimmune disease. Its expression cassettes can be incorporated into both viral and non-viral delivery vehicles such as lentivirus, AAV, lipid and polymeric nanoparticles, and exosomes.

1 investor

Impact Medical Innovations develops diagnostic technologies for detecting ovarian and prostate cancer, with a focus on creating affordable, accessible point-of-care solutions to address global healthcare gaps.

1 investor

Implexis blends pharmaceutical expertise with automation to deliver impact in the life sciences industry.

1 investor

Impli develops implantable biotech devices that enable continuous monitoring of biological data, starting with hormone monitoring applications. The platform is designed to support personalized, preventive healthcare by tracking real-time shifts in stress, fertility, metabolism, and aging.

1 investor

Impulse Dynamics develops implantable medical device technology for cardiac care, with a background in biomedical research and implantable cardiac electronics. The company operates in the cardiovascular medical device industry.

1 investor

Imtherapeutics develops oral therapies for Type 1 diabetes patients with specific genetic markers. The company's AMT-002 candidate is designed to selectively block autoantigens that trigger autoimmunity in patients with the HLA-DQ8 genetic allele.

1 investor

Immunic is a clinical-stage biopharmaceutical company developing oral small molecule treatments for neurologic and autoimmune diseases with unmet medical needs.

1 investor

IMV Technologies develops artificial insemination and reproductive biotechnology products for animal reproduction and veterinary imaging, including semen collection and storage, wireless ultrasound, pregnancy confirmation, and reproduction data management. It serves farmers, veterinarians, and livestock producers, with a focus on sustainable farming and animal health.

1 investor

A clinical-stage biotechnology company developing allogeneic CAR-T cell therapies for oncology and autoimmune diseases, targeting off-the-shelf and scalable treatments to improve patient access.

1 investor

Incanthera develops and commercializes therapeutics derived from the Institute of Cancer Therapeutics in Bradford. The company operates a direct-to-consumer model with a global network of influencers and ambassadors, targeting multi-billion dollar markets outside the US.

1 investor

Incisive Genetics develops non-viral gene editing therapeutics using proprietary lipid nanoparticle delivery technology to treat genetic diseases by editing genes directly in target tissues. The company focuses initially on Huntington's disease and is advancing toward human clinical trials.

1 investor

Incredible produces a low-sugar fruit juice marketed as containing 70% less sugar than regular juice, around 30 calories, and 5g of fiber while being 100% juice. The company sells the beverage to retail stores.

1 investor

InCurA develops medical devices focused on bleeding control and hemostatic solutions for surgical, dental, and emergency applications, with manufacturing and distribution across the MENA region and GCC countries. The company uses machine learning-optimized R&D to identify medical needs and commercialize biomedical innovations in markets with access gaps.

1 investor

Incyte is a biopharmaceutical company that develops and commercializes medicines for oncology, hematology, dermatology, and other therapeutic areas. The company focuses on bringing treatments to patients across multiple disease categories.

1 investor

Indee Labs develops Hydropore™, a non-viral microfluidic technology for delivering molecules, nucleic acids, proteins, and gene-editing complexes into immune cells for engineered cell therapy research and manufacturing. The platform enables rapid production of high-quality T-cell immunotherapies and other cell therapies with preserved cell function.

1 investor

Indegene provides technology-enabled commercial solutions and consulting services for life sciences and healthcare enterprises, helping them optimize customer experiences, content management, and data-driven decision-making across their commercial operations.

1 investor